Irbesartan Hydrochlorothiazide Zentiva

Irbesartan, the active ingredient in Irbesartan Hydrochlorothiazide Zentiva, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is combined with hydrochlorothiazide, a thiazide diuretic, to treat hypertension in adult patients who need additional blood pressure control beyond monotherapy, and is included in standard hypertension management guidelines.

GNH USA supplies Irbesartan Hydrochlorothiazide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable quality assurance, regulatory compliance and on‑time delivery for global healthcare partners.

Irbesartan/Hydrochlorothiazide is used to manage hypertension, a condition characterized by elevated arterial pressure.

- Essential hypertension: lowers systolic and diastolic blood pressure. - Secondary hypertension: improves blood pressure control when underlying causes are present. - Hypertension with fluid retention: reduces excess fluid and aids in achieving target blood pressure.

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Fatigue or weakness. - Increased urination. - Electrolyte disturbances (e.g., low potassium). - Mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance. - Acute kidney injury. - Hyperkalemia. - Angioedema or severe swelling. - Significant hypotension. - Allergic skin reactions.

Patients should be monitored for safety and optimal therapeutic effect. - Blood pressure monitoring: check regularly to ensure target levels are reached. - Renal function assessment: evaluate serum creatinine and eGFR before and during treatment. - Electrolyte surveillance: monitor potassium and sodium levels. - Pregnancy warning: avoid use in pregnancy due to fetal risk. - Elderly caution: start at lower dose and watch for orthostatic hypotension. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines; careful review is essential.

Major Interactions (Avoid): - Aliskiren in patients with diabetes: risk of renal impairment. - Potassium‑sparing diuretics or supplements: may cause hyperkalemia. - Lithium: increased lithium toxicity. - ACE inhibitors or other ARBs: additive effects on potassium and renal function. - NSAIDs: may reduce antihypertensive efficacy and impair renal function.

Moderate Interactions (Monitor Closely): - Other antihypertensives: may enhance blood pressure lowering. - CYP450 inhibitors (e.g., fluconazole): can increase irbesartan levels. - Loop diuretics: monitor electrolytes and volume status. - Antidiabetic agents: may require dose adjustment due to blood pressure changes. - Anticoagulants: monitor for increased bleeding risk.